Related Experiment Videos
SIV envelope glycoprotein epitopes recognized by antibodies from infected or vaccinated rhesus macaques
J V Torres1, D E Anderson, A Malley
1Department of Microbiology and Immunology, School of Medicine, University of California, Davis 95616.
Abstract:
We analyzed SIV-specific monkey sera to localize B-cell epitopes of the envelope glycoprotein of SIV (gp130), using overlapping synthetic peptides representing the entire SIV gp130 protein and sera from experimentally infected monkeys and monkeys immunized with whole, inactivated SIV. A B-cell epitope which induces neutralizing antibody production and T-cell responses was characterized as well as a new B-cell epitope and a previously described neutralizing epitopes. Vaccinated monkey sera recognize the three epitopes differentially relative to unimmunized controls, and a correlation appears to exist between degree of cross-neutralization by infected monkey sera and degree of binding to these three regions.
Insights
Researchers mapped key areas on the SIV envelope glycoprotein (gp130) that trigger immune responses. These findings are crucial for developing effective vaccines against Simian Immunodeficiency Virus (SIV).
Area of Science:
- Immunology
- Virology
- Vaccine Development
Background:
- The envelope glycoprotein of Simian Immunodeficiency Virus (SIV), known as gp130, is a primary target for neutralizing antibodies.
- Understanding B-cell epitopes on gp130 is critical for designing effective SIV vaccines.
Purpose of the Study:
- To identify and characterize B-cell epitopes on the SIV gp130 envelope glycoprotein.
- To analyze the immune response to these epitopes in experimentally infected and immunized monkeys.
Main Methods:
- Analysis of SIV-specific monkey sera against overlapping synthetic peptides of the SIV gp130 protein.
- Utilizing sera from experimentally infected and SIV-immunized monkeys.
Main Results:
- Characterization of a novel B-cell epitope that elicits neutralizing antibodies and T-cell responses.
- Identification of a previously described neutralizing epitope and a new B-cell epitope.
- Differential recognition of these three epitopes by sera from vaccinated versus unimmunized monkeys.
- Correlation observed between cross-neutralization by infected monkey sera and binding to these epitopes.
Conclusions:
- The study successfully localized key B-cell epitopes on SIV gp130.
- These identified epitopes are important targets for SIV vaccine development, influencing antibody production and cross-neutralization.
- Differential immune recognition suggests epitope-specific vaccine strategies may be viable.